Cobitolimod for Moderate-to-Severe Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial

Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hebuterne X, Arnesson K, Knittel T, Kowalski J, Neurath M, Sandborn WJ, Reinisch W (2020)


Publication Type: Conference contribution

Publication year: 2020

Journal

Publisher: LIPPINCOTT WILLIAMS & WILKINS

City/Town: PHILADELPHIA

Pages Range: S322-S322

Conference Proceedings Title: AMERICAN JOURNAL OF GASTROENTEROLOGY

DOI: 10.1016/s2468-1253(20)30301-0

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Atreya, R., Peyrin-Biroulet, L., Klymenko, A., Augustyn, M., Bakulin, I., Slankamenac, D.,... Reinisch, W. (2020). Cobitolimod for Moderate-to-Severe Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial. In AMERICAN JOURNAL OF GASTROENTEROLOGY (pp. S322-S322). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

MLA:

Atreya, Raja, et al. "Cobitolimod for Moderate-to-Severe Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial." Proceedings of the AMERICAN JOURNAL OF GASTROENTEROLOGY PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2020. S322-S322.

BibTeX: Download